MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00134-026-08381-x

Медицинская библиотека · Intensive care medicine · 2026

Short-term light sedation with remimazolam besylate versus propofol in the ICU (SHOSREB): a multicentre, randomized, single-blind, controlled trial.

Yang Xiaobo, Pan Jingye, Gong Xun, Lv Ailian, Liang Fengming, Liu Jing, Li Dezhong, Fu Shouzhi, Pan Aijun, Yu Li, Zhang Lina, Chen Tao, Zhan Liying, Qin Bingyu, Lin Fenghui, Xiong Xuming, Zhu Ying, He Zhihui, Sun Renhua, Sun Tongwen, Qian Songzan, Wen Deliang, Zou Xiaojing, Qi Hong, Shu Huaqing, Song Liping, Wang Chunhua, Shang You

СтатьяРандомизированное исследованиеМногоцентровое исследованиеСравнительное исследованиеПеревод в очереди

Аннотация

PURPOSE: To explore the efficacy and safety of remimazolam besylate in short-term sedation in the ICU in comparison with propofol.

METHOD: A multicenter, randomized, single-blind, non-inferiority trial was conducted in mechanically ventilated patients, who needed light sedation, defined as Richmond Agitation-Sedation Scale (RASS) scores between -2 and + 1. The primary outcome was successful sedation, which was defined as no rescue sedative administered during the study drug infusion period while maintaining RASS scores between -2 and + 1 for at least 70% of the total infusion time.

RESULTS

A total of 164 participants were included and randomized equally into the remimazolam group and the propofol group. Remimazolam was continuously infused for 10.5 [8.1-14.7] h and propofol for 11.0 [7.0-14.3] h (p = 0.534). The median average maintaining dose of remimazolam and propofol was 0.20 [0.19-0.30] mg·kg⁻1·h⁻1 and 0.61 [0.30-1.17] mg·kg⁻1·h⁻1, respectively. The percentage of participants successfully sedated in both groups was 97.5% (p = 0.497) with a difference of 0 (95% confidence interval (CI) -6.5% to 6.4%), above the predefined non-inferiority margin of -8%. There was no significant difference in the mean percentage of time with target RASS scores between the remimazolam group (88.6%; 95% CI: 84.2%-92.9%) and the propofol group (89.4%; 95% CI: 85.0%-93.8%) (p = 0.543).

CONCLUSION

Remimazolam besylate could be non-inferior to propofol for achieving successful short-term light sedation in the ICU.

TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT05782894 on Feb 18th, 2023.

Для цитирования: Yang Xiaobo, Pan Jingye, Gong Xun, Lv Ailian, Liang Fengming, Liu Jing, Li Dezhong, Fu Shouzhi, Pan Aijun, Yu Li, Zhang Lina, Chen Tao, Zhan Liying, Qin Bingyu, Lin Fenghui, Xiong Xuming, Zhu Ying, He Zhihui, Sun Renhua, Sun Tongwen, Qian Songzan, Wen Deliang, Zou Xiaojing, Qi Hong, Shu Huaqing, Song Liping, Wang Chunhua, Shang You. Short-term light sedation with remimazolam besylate versus propofol in the ICU (SHOSREB): a multicentre, randomized, single-blind, controlled trial.. Intensive care medicine. 2026. DOI: 10.1007/s00134-026-08381-x.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.